Elicio Therapeutics Company
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Last Funding Type:
Series B
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2011
Investor Type:
Early Stage Venture
Last Funding Date:
2021
Total Funding:
148461801
Employee Number:
11-50
Estimated Revenue:
Less than $1M
Investors Number:
5
Industry:
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics